BioCentury | Jan 20, 2014

Independent streak

Alnylam Pharmaceuticals Inc. 's deals with Genzyme Corp. and Merck & Co. Inc. are designed to give the RNAi pioneer the wherewithal to deliver value to its shareholders for the next five to 10 years...
BioCentury | Jan 13, 2014
Company News

Alnylam infectious, endocrine/metabolic, cancer news

Alnylam provided a pipeline update and said it expects to have six to seven programs in clinical development by YE15, exceeding the goals set in the company's original "Alnylam 5x15" plan. The company said it...
BioCentury | Jan 21, 2013
Clinical News

Alnylam preclinical data

In a mouse model of beta-thalassemia, ALN-TMP reduced the severity of anemia as demonstrated by an approximate 1 g/dL increase in total hemoglobin and a 50% reduction in circulating erythropoietin levels. ALN-TMP also reduced serum...
BioCentury | May 3, 2012
Distillery Therapeutics

Indication: Hematology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Thalassemia Hepcidin antimicrobial peptide (HAMP); transmembrane protease serine 6 (TMPRSS6; matriptase-2) Mouse studies suggest inhibiting TMPRSS6 could help treat b-thalassemia. In a mouse model of...
BioCentury | Jan 23, 2012
Company News

Alnylam endocrine/metabolic, hematology news

Alnylam said it will restructure and reduce headcount by 61 (33%) to about 115 to focus on development of its ALN-TTR and ALN-APC programs. The programs are part of Alnylam's 5x15 strategy aimed at moving...
BioCentury | Jan 21, 2012
Company News

Alnylam restructuring

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said it will restructure and reduce headcount by 61 (35%) to 115 following a decision this month to partner three of the five RNAi therapeutic programs it is hoping to move...
Items per page:
1 - 6 of 6